ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Rain Oncology Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – RAIN
NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July
EB5 Capital’s Columbia Place (JF9) Project Receives I-829 Approvals
WASHINGTON, Aug. 03, 2023 (GLOBE NEWSWIRE) — Today, EB5 Capital announced that investors in its Columbia Place (JF9) project have started receiving I-829 approvals from the United States Citizenship and
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Party City Holdco Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– PRTY, PRTYQ
NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers
ibex Wins Top Exporter Award in Pakistan
ibex Wins Top Exporter Award in Pakistan ISLAMABAD, Pakistan, Aug. 03, 2023 (GLOBE NEWSWIRE) — ibex (NASDAQ: IBEX), a leading global provider of business process outsourcing (BPO) and customer engagement
Abu Dhabi’s artificial intelligence university establishes dedicated robotics and computer science departments to meet surging global demand
ABU DHABI, United Arab Emirates, Aug. 03, 2023 (GLOBE NEWSWIRE) — Mohamed bin Zayed University of Artificial Intelligence (MBZUAI) has established two new departments and four associated graduate programs dedicated
Zenas BioPharma Announces Publication of Phase 2 Study of Obexelimab, an Investigational Treatment for IgG4-Related Disease (IgG4-RD), in The Lancet Rheumatology
Study found obexelimab produced rapid, strong, and sustained clinical improvement, including complete clinical remission, in most patients with active IgG4-RD Results support the continued development of obexelimab for the treatment